Comorbid obsessive-compulsive disorder and Tourette syndrome: Therapeutic interventions

CNS Drugs

Volumn 13, Issue 3, 2000, Pages 173-183

  Eapen, Valsamma ^a,b   Robertson, Mary M ^b  

^a UNITED ARAB EMIRATES UNIVERSITY   (United Arab Emirates)

^b ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CLOMIPRAMINE; CLONAZEPAM; CLONIDINE; CLOZAPINE; DOPAMINE RECEPTOR BLOCKING AGENT; FLUOXETINE; FLUVOXAMINE; GUANFACINE; HALOPERIDOL; NEUROLEPTIC AGENT; OLANZAPINE; PAROXETINE; PIMOZIDE; RISPERIDONE; SEROTONIN UPTAKE INHIBITOR; SERTRALINE;

ARTICLE; COMORBIDITY; DRUG EFFICACY; DRUG INDUCED DISEASE; DRUG TOLERABILITY; GILLES DE LA TOURETTE SYNDROME; HUMAN; OBSESSION; PRIORITY JOURNAL; RISK BENEFIT ANALYSIS;

EID: 0034059683     PISSN: 11727047     EISSN: None     Source Type: Journal    
DOI: 10.2165/00023210-200013030-00004     Document Type: Article

References (111)

1. 1. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 4th ed. Washington, DC: American Psychiatric Association, 1994
2. 2. World Health Organisation. International classification of diseases and health related problems - tenth revision. Geneva: World Health Organisation, 1992
3. 3. Eapen V, Robertson MM, Alsobrook JP, et al. Obsessive compulsive symptoms in Gilles de la Tourette syndrome and obsessive compulsive disorder: differences by diagnosis and family history. Am J Med Genet 1997; 74: 432-8
4. 4. Pauls DL, Towbin KE, Leckman JF, et al. Gilles de la Tourette's syndrome and obsessive-compulsive disorder: evidence supporting a genetic relationship. Arch Gen Psychiatry 1986; 43: 1180-2
5. 5. Eapen V, Pauls DL, Robertson MM. Evidence for autosomal dominant gene transmission in Tourette Syndrome. Br J Psychiatry 1993 62: 593-6
6. 6. Peterson BS. Considerations of natural history and pathophysiology in the psychopharmacology of Tourette's syndrome. J Clin Psychiatry 1996; 57 (9): 24-34
7. 7. Shapiro E, Shapiro AK, Fulop G, et al. Controlled study of haloperidol, pimozide, and placebo for the treatment of Gilles de la Tourette's syndrome. Arch Gen Psychiatry 1989; 46: 722-30
8. 8. Sallee FR, Nesbitt L, Jackson C, et al. Relative efficacy of haloperidol and pimozide in children and adolescents with Tourette's disorder. Am J Psychiatry 1997; 154 (8): 1057-62
9. 9. Robertson MM, Schnieden V, Lees AJ. Management of Gilles de la Tourette syndrome using sulpiride. Clin Neuropharmacol 1990; 13 (3): 229-35
10. 10. Eggers CH, Rothenberger A, Berghaus U. Clinical and neurobiological findings in children suffering from tic disease following treatment with liapride. Eur Arch Psychiatry Neurol Sci 1988; 237: 223-9
11. 11. Sallee FR, Dougherty D, Sethuraman G, et al. Prolactin monitoring of haloperidol and pimozide treatment in children with Tourette's syndrome. Biol Psychiatry 1996; 40 (10): 1044-50
12. 12. Regeur L, Pakkenberg B, Fog R, et al. Clinical features and long-term treatment with pimozide in 65 patients with Gilles de la Tourette's syndrome. J Neurol Neurosurg Psychiatry 1986; 49: 791-5
13. 13. Robertson MM. Tourette syndrome, associated conditions and the complexities of treatment. Brain. In press
14. 14. Mikkelsen EJ, Detlor J, Cohen DJ. School avoidance and school phobia triggered by haloperidol in patients with Tourette's disorder. Am J Psychiatry 1981; 138 (12): 1572-6
15. 15. Robertson MM, Scull DA, Eapen V, et al. Risperidone in the treatment of Tourette syndrome: a retrospective case note study. J Psychopharmacol 1996; 10 (4): 317-20
16. 16. Cosgrove F. Recent advances in paediatric psychopharmacology. Hum Psychopharmacol 1994; 9: 381-2
17. 17. Caine ED, Polinsky RJ, Ebert MH, et al. Trial of clorimpramine and desipramine for Gilles de la Tourette syndrome. Ann Neurol 1979; 6: 305-6
18. 18. Bhandrinath BR. Olanzapine in Tourette syndrome [letter]. Br J Psychiatry 1998; 172: 366
19. 19. Leckman JF, Detlor J, Harcherick DF, et al. Short and long-term treatment of Tourette's syndrome with clonidine: a clinical perspective. Neurology 1985; 35: 343-51
20. 20. Lichter DG, Jackson LA. Predictors of clonidine response in Tourette syndrome: implications and inferences. J Child Neurol 1996; 11 (2): 93-7
21. 21. Oesterheld J, Tervo R. Clonidine: a practical guide for usage in children. SDJ Med 1996; 49 (7) 234-7
22. 22. Chappell PB, Riddle MA, Scahill L, et al. Guanfacine treatment of comorbid attention-deficit hyperactivity disorder and Tourette's syndrome: preliminary clinical experience. J Am Acad Child Adolesc Psychiatry 1995; 34 (9): 1140-6
23. 23. Fras I. Guanfacine for Tourette's disorder. J Am Acad Child Adolesc Psychiatry 1996; 35 (1): 3-4
24. 24. Goetz CG. Clonidine and clonazepam in Tourette syndrome. Adv Neurol 1992; 58: 245-51
25. 25. LeWitt PA. Therapeutics of Tourette Syndrome. New medication approaches. Adv Neurol 1992; 58: 263-70
26. 26. Silver AA, Sanberg PR. Transdermal nicotine patch and potentiation of haloperidol in Tourette's syndrome [letter]. Lancet 1993; 342 (8864): 182
27. 27. Desai AB, Doongaji DR, Satoskar RS. Metoclopramide in Gilles de la Tourette's syndrome. J Postgrad Med 1983; 29: 181-3
28. 28. Hemming M, Yellowlees PM. Effective treatment of Tourette's syndrome with marijuana. J Psychopharmacol 1993; 7: 389-91
29. 29. Lipinski JF, Sallee FR, Jackson C, et al. Dopamine agonist treatment of Tourette disorder in children: results of an open-label trial of pergolide. Mov Disord 1997; 12 (3): 402-7
30. 30. Peterson BS, Zhang H, Anderson GM, et al. A double-blind, placebo-controlled, crossover trial of an antiandrogen in the treatment of Tourette's syndrome. J Clin Psychopharmacol 1998; 18 (4): 324-31
31. 31. Trimble MR, Whurr R, Brookes G, et al. Vocal tics in Gilles de la Tourette Syndrome treated with botulinum toxin injections. Mov Disorders 1998; 13 (3): 617-9
32. 32. Fineberg NA, Bullock T, Montgomery DB, et al. Serotonin reuptake inhibitors are the treatment of choice in obsessive-compulsive disorder. Int Clin Psychopharmacol 1992; 7 Suppl. 1: 43-7
33. 33. Pigott TA, Seay SM. A review of the efficacy of selective serotonin reuptake inhibitors in obsessive-compulsive disorder. J Clin Psychiatry 1999; 60 (2): 101-6
34. 34. Greist JH, Jefferson JW. Pharmacotherapy for obsessive-compulsive disorder. Br J Psychiatry 1998; 173 (35): 64-70
35. 35. De Veaugh-Geiss J, Moroz G, Biederman J, et al. Clomipramine hydrochloride in childhood and adolescent obsessive-compulsive disorder - a multicenter trial. J Am Acad Child Adolesc Psychiatry 1992; 31 (1): 45-9
36. 36. De Vaugh-Geiss J, Katz R, Landau P, et al. Clomipramine in the treatment of patients with obsessive-compulsive disorder: the clomipramine collaborative study group. Arch Gen Psychiatry 1991; 48: 730-8
37. 37. Hollander E, Stein DJ, Decaria CM, et al. Disorders related to OCD-neurobiology. Clin Neuropharmacol 1992; 15 Suppl. 1: 259A-60A
38. 38. March JS, Johnston H, Jefferson JW, et al. Do subtle neurological impairments predict treatment resistance to clomipramine in children and adolescents with obsessive compulsive disorder? J Child Adolesc Psychopharmacol 1990; 1: 133-40
39. 39. Leonard HL, Swedo SE, Rapoport JL, et al. Treatment of obsessive-compulsive disorder with clomipramine and desipramine in children and adolescents: a double-blind crossover comparison. Arch Gen Psychiatry 1989; 46: 1088-92
40. 40. De Veaugh-Geiss J, Katz R, Landau P, et al. Clinical predictors of treatment response in obsessive-compulsive disorder: exploratory analyses from multicenter trials of clomipramine. Psychopharmacol Bull 1990; 26: 45-9
41. 41. Ratzoni G, Hermesh H, Brandt N, et al. Clomipramine efficacy for tics, obsessions, and compulsions in Tourette's syndrome and obsessive-compulsive disorder: a case study. Biol Psychiatry 1990; 27: 95-8
42. 42. Yaryura-Tobias JA. Clomipramine in Gilles de la Tourette disease [letter]. Am J Psychiatry 1975; 132 (11): 1221
43. 43. Riddle MA, Hardin MT, Cho SC, et al. Desipramine treatment of boys with attention-deficit hyperactivity disorder and tics: preliminary clinical experience. J Am Acad Child Adolesc Psychiatry 1988; 27: 811-4
44. 44. Hoge SK, Biederman J. A case of Tourette's syndrome with symptoms of attention deficit disorder treated with desipramine. J Clin Psychiatry 1986; 47: 478-9
45. 45. Lambert MV, Robertson MM. Depression in epilepsy: etiology, phenomenology and treatment. Epilepsia 1999; 40 Suppl. 10: S21-47
46. 46. Fuller RW, Wong DT. Serotonin reuptake blockers in vitro and in vivo. J Clin Psychopharmacol 1987; 7: 36S-43S
47. 47. Hollander E. Treatment of obsessive-compulsive spectrum disorders with SSRIs. Br J Psychiatry 1998; 173 (35): 7-12
48. 48. Montgomery SA, McIntyre A, Osterheider M, et al. A double-blind, placebo-controlled study of fluoxetine in patients with DSM-III-R obsessive-compulsive disorder. The Lilly European OCD Study Group. Eur Neuropsychopharmacol 1993; 3 (2): 143-52
49. 49. Leonard HL, Swedo SE, Lenane MC, et al. A 2-to 7-year follow up study of 54 obsessive-compulsive children and adolescents. Arch Gen Psychiatry 1993; 50 (6): 429-39
50. 50. Goodman WK, Price LH, Delgado PL, et al. Specificity of serotonin reuptake inhibitors in the treatment of obsessive-compulsive disorder: comparison of fluvoxamine and desipramine. Arch Gen Psychiatry 1990; 47: 577-85
51. 51. Jenike MA, Baer, Summergrad P, et al. Sertraline in obsessive-compulsive disorder: a double-blind comparison with placebo. Am J Psychiatry 1990; 147: 923-8
52. 52. Chouinard G, Goodman WK, Greist J, et al. Results of a double-blind placebo controlled trial of a new serotonin uptake inhibitor, sertraline, in the treatment of obsessive-compulsive disorder. Psychopharmacol Bull 1990; 26: 279-84
53. 53. Thomsen PH. Child and adolescent obsessive-compulsive disorder treated with citalopram: findings from an open trial of 23 cases. J Child Adolesc Psychopharmacol 1997; 7 (3): 157-66
54. 54. Zohar J, Judge R. Paroxetine versus clomipramine in the treatment of obsessive-compulsive disorder. OCD Paroxetine Study Investigators. Br J Psychiatry 1996; 169 (4): 468-74
55. 55. Mundo E, Bianchi L, Bellodi L. Efficacy of fluvoxamine, paroxetine, and citalopram in the treatment of obsessive-compulsive disorder: a single-blind study. J Clin Psychopharmacol 1997; 17 (4): 267-71
56. 56. DeVane CL, Pharm D, Sallee FR. Serotonin selective reuptake inhibitors in child and adolescent psychopharmacology: a review of published experience. J Clin Psychiatry 1996; 57: 55-66
57. 57. Riddle M. Obsessive-compulsive disorder in children and adolescents. Br J Psychiatry 1998; 35 Suppl.: 91-6
58. 58. Flament MF, Rappoport JL, Berg CZ, et al. Clomipramine treatment of childhood obsessive-compulsive disorder. A double-blind controlled study. Arch Gen Psychiatry 1985; 42 (10): 977-83
59. 59. Riddle MA, Scahill L, King RA et al. Double blind crossover trial of fluoxetine and placebo in children and adolescents with obsessive compulsive disorder. J Am Acad Child Adolesc Psychiatry 1992; 31: 1062-9
60. 60. March JS, Biederman J, Workow R, et al. Sertraline in children and adolescents with obsessive-compulsive disorder: a multicenter randomized controlled trial. JAMA 1998; 280 (20): 1752-6
61. 61. Riddle MA, King RA, Hardin MT, et al. Behavioral side effects of fluoxetine in children and adolescents. J Child Adolesc Psychopharmacol 1991; 1: 193-8
62. 62. Eapen V, Trimble MR, Robertson MM. The use of fluoxetine in Gilles de la Tourette syndrome and obsessive compulsive behaviours: preliminary clinical experience. Prog Neuropsychopharmacol Biol Psychiatry 1996; 20: 737-43
63. 63. Pato MT, Pigott TA, Hill JL, et al. Controlled comparison of buspirone and clomipramine in obsessive-compulsive disorder. Am J Psychiatry 1991; 148: 127-9
64. 64. Jenike MA, Baer L. An open trial of buspirone in obsessive-compulsive disorder. Am J Psychiatry 1988; 145: 1285-6
65. 65. Hewlett WA, Vinogradov S, Agras WS. Clonazepam treatment of obsessions and compulsions. J Clin Psychiatry 1990; 51: 158-61
66. 66. Bodkin JA, White K. Clonazepam in the treatment of obsessive-compulsive disorder associated with panic disorder in one patient. J Clin Psychiatry 1989; 50: 265-6
67. 67. Pratt J, Jenner P, Reynolds EH, et al. Clonazepam induces decreased serotoninergic activity in the mouse brain. Neuropharmacology 1979; 18: 791-9
68. 68. McDougle CJ, Price LH, Goodman WK, et al. A controlled trial of lithium augmentation in fluvoxamine-refractory obsessive-compulsive disorder: lack of efficacy. J Clin Psychopharmacol 1991; 11: 175-84
69. 69. Stein DJ, Bouwer C, Hawkridge S, et al. Risperidone augmentation of serotonin reuptake inhibitors in obsessive-compulsive and related disorder. J Clin Psychiatry 1997; 58 (3): 119-22
70. 70. Jacobsen FM. Risperidone in the treatment of affective illness and obsessive-compulsive disorder. J Clin Psychiatry 1995; 56: 423-9
71. 71. King RA, Riddle MA, Goodman WK. Psychopharmacology of obsessive compulsive disorder in Tourette syndrome. Adv Neurol 1992; 58: 283-91
72. 72. Rasmussen SA. Lithium and tryptophan augmentation in clomipramine resistant obsessive-compulsive disorder. Am J Psychiatry 1984; 141: 1283-5
73. 73. Golden RN, Morris JE, Sack DA. Combined lithium-tricyclic treatment of obsessive-compulsive disorder. Biol Psychiatry 1988; 23: 181-5
74. 74. Jenike MA, Baer L, Buttolph L. Buspirone augmentation of fluoxetine in patients with obsessive-compulsive disorder. J Clin Psychiatry 1991; 52: 13-4
75. 75. Markovitz PJ, Stagno SJ, Calabrese JR. Buspirone augmentation of fluoxetine in obsessive-compulsive disorder. Am J Psychiatry 1990; 147: 798-800
76. 76. Pigott TA, L'Heurex F, Hill JL, et al. A double blind study of adjuvant buspirone hydrochloride in clomipramine treated patients with obsessive compulsive disorder. J Clin Psychopharmacol 1992; 12 (1): 11-8
77. 77. Grady TA, Pigott TA, L'Heureux F, et al. Double-blind study of adjuvant buspirone for fluoxetine-treated patients with obsessive-compulsive disorder. Am J Psychiatry 1993; 150 (5): 819-21
78. 78. McDougle CJ, Goodman WK, Leckman JF, et al. Limited therapeutic effect of addition of buspirone in fluvoxamine-refractory obsessive-compulsive disorder. Am J Psychiatry 1993; 150 (4): 647-9
79. 79. Figueroa Y, Rosenberg DR, Birmaher B, et al. Combination treatment with clomipramine and selective serotonin reuptake inhibitors for obsessive-compulsive disorder in children and adolescents. J Child Adolesc Psychopharmacol 1998; 8 (1): 61-7
80. 80. Leonard HL, Topol D, Bukstein O, et al. Clonazepam as an augmenting agent in the treatment of childhood-onset obsessive-compulsive disorder. J Am Acad Child Adolesc Psychiatry 1994; 33 (6): 792-4
81. 81. Hand I. Out-patient, multi-modal behaviour therapy for obsessive-compulsive disorder. Br J Psychiatry 1998; 173 (35): 45-52
82. 82. Salkovskis PM, Forrester E, Richards C. Cognitive-behavioural approach to understanding obsessional thinking. Br J Psychiatry 1998; 173 (35): 53-63
83. 83. O'Sullivan G, Nishirvani H, Marks L, et al. Six year follow up after exposure and clomipramine therapy for obsessive-compulsive disorder. J Clin Psychiatry 1991; 52: 150-5
84. 84. Foa, EB, Kozak MJ. Psychological treatment for obsessive-compulsive disorder. In: Mavissakalian MR, Prien RF, editors. Long-term treatments of anxiety disorders. Washington, DC: American Psychiatric Press, 1996: 285-309
85. 85. March JS, Mulle K, Herbel B. Behavioral psychotherapy for children and adolescents with obsessive-compulsive disorder: an open trial of a new protocol-driven treatment package. J Am Acad Child Adolesc Psychiatry 1994; 33: 333-41
86. 86. Orloff LM, Battle MA, Baer L, et al. Long-term follow-up of 85 patients with obsessive-compulsive disorder. Am J Psychiatry 1994; 151: 441-2
87. 87. Lucey JV, Butcher G, Clare AW, et al. The clinical characteristics of patients with obsessive compulsive disorder: a descriptive study of an Irish sample. Ir J Psychol Med 1994; 11: 11-4
88. 88. Hohagen F, Winkelmann G, Rasche-Rauchle H, et al. Combination of behaviour therapy with fluvoxamine in comparison wilth behaviour therapy and placebo. Results of a multicentre study. Br J Psychiatry 1998; 173 (35): 71-8
89. 89. Mindus P, Rauch SL, Nyman H, et al. Capsulotomy and cingulotomy as treatments for malignant obsessive-compulsive disorder. In: Hollander E, Zohar J, Marazziti D, et al., editors. Current insights in obsessive-compulsive disorder. Chichester: John Wiley & Sons, 1994: 245-76
90. 90. Baer L, Rauch SL, Ballantine Jr HT, et al. Cingulotomy for intractable obsessive-compulsive disorder: prospective long-term follow-up of 18 patients. Arch Gen Psychiatry 1995; 52: 384-92
91. 91. Graybiel AM. Neurotransmitters and neuromodulators in the basal ganglia. Trends Neurosci 1990; 13: 244-54
92. 92. Liebowitz MR, Hollander E, Schneier F, et al. Fluoxetine treatment of obsessive-compulsive disorder: an open clinical trial. J Clin Psychopharmacol 1989; 9: 423-7
93. 93. Jenike MA, Buttolph L, Baer L, et al. Open trial of fluoxetine in obsessive-compulsive disorder. Am J Psychiatry 1989; 146: 909-11
94. 94. Levine R, Hoffman JS, Knepple ED, et al. Long-term fluoxetine treatment of a large number of obsessive-compulsive patients. J Clin Psychopharmacol 1989; 9: 281-3
95. 95. Riddle MA, Hardin MT, King R, et al. Fluoxetine treatment of children and adolescents with Tourette's and obsessive compulsive disorders: preliminary clinical experience. J Am Acad Child Adolesc Psychiatry 1990; 29 (1): 45-8
96. 96. Como PG, Kurlan R. An open label trial of fluoxetine for obsessive compulsive disorder in Gilles de la Tourette Syndrome. Neurology 1991; 41: 872-4
97. 97. Kurlan R, Como PG, Deeley C et al. A pilot controlled study of fluoxetine for obsessive compulsive symptoms in children with Tourette syndrome. Clin Neuropharmacol 1993; 16 (2): 167-72
98. 98. Scahill L, Riddle MA, King RA, et al. Fluoxetine has no marked effect on tic symptoms in patients with Tourette's syndrome: a double-blind placebo-controlled study. J Child Adolesc Psychopharmacol 1997; 7: 75-85
99. 99. George MS, Trimble MR, Robertson MM. Fluvoxamine and sulpiride in comorbid obsessive-compulsive disorder and Gilles de la Tourette syndrome. Hum Psychopharmacol 1993; 8: 327-34
100. 100. Bruun RD, Budman CL. Paroxetine treatment of episodic rages associated with Tourette's disorder. J Clin Psychiatry 1998; 59 (11): 5812-4
101. 101. Bajo S, Battaglia M, Pegna C, et al. Citalopram and fluvoxamine in Tourette's disorder. J Am Acad Child Adolesc Psychiatry 1999; 38 (3): 230-1
102. 102. Gonce M, Barbeau A. Seven cases of Gilles de la Tourette syndrome: partial relief with clonazepam: a pilot study. Can J Neurol Sci 1977; 4: 279-83
103. 103. Kaim B. A case of Gilles de la Tourette's syndrome treated with clonazepam. Brain Res Bull 1983; 11: 213-4
104. 104. Merikangas JR, Merikangas KR, Kopp U, et al. Blood choline and response to clonazepam and haloperidol in Tourette's syndrome. Acta Psychiatry Scand 1985; 72: 395-9
105. 105. Truong DD, Bressman S, Shale H. Clonazepam, haloperidol, and clonidine in tic disorders. South Med J 1988; 81: 1103-5
106. 106. McDougle CJ, Goodman WK, Leckman JF, et al. Haloperidol addition in fluvoxamine refractory obsessive compulsive disorder. Arch Gen Psychiatry 1994; 51: 302-8
107. 107. Delgado PL, Goodman WK, Price LH, et al. Fluvoxamine/ pimozide treatment of concurrent Tourette's and obsessive-compulsive disorder. Br J Psychiatry 1990; 157: 762-5
108. 108. Fennig S, Fennig SN, Pato M, et al. Emergence of symptoms of Tourette's syndrome during fluvoxamine treatment of obsessive-compulsive disorder. Br J Psychiatry 1994; 164 (6): 839-41
109. 109. Swedo SE, Leonard HL. Childhood movement disorders and obsessive compulsive disorder. J Clin Psychiatry 1994; 55 (3): 32-7
110. 110. Sandor P. Clinical management of Tourette's syndrome and associated disorders. Can J Psychiatry 1995; 40: 577-83
111. 111. Hawkridge S, Stein DJ, Bourwer C. Combined pharmacotherapy for TS and OCD. J Am Acad Child Adolesc Psychiatry 1996; 35: 703-4